Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Featured Story

    The Real Story Behind JPMorgan's Infamous "Whale" Trade

    Here's an insight for you - along with a trademark indictment, of course.

    Take it with a grain of salt, because it's just an educated guess on my part.

    It's about how the infamous London Whale may have been harpooned by spawn from his own pod.

    For those who haven't heard, the London Whale is one of the latest traders to make the headlines. Bruno Iksil was the top trader at JPMorgan Chase's Chief Investment Office (CIO) in London.

    He got the nickname "the London Whale" for the outsized bets he became known for.

    But this is no fish story...

    To continue reading, please click here…


    Read More...
  • jp morgan trades